Publications by authors named "M Tretyakova"
Article Synopsis
- - Thrombotic microangiopathy (TMA) is a group of disorders where small blood vessel clotting causes organ damage, including conditions like thrombotic thrombocytopenic purpura (TTP) and hemolytic-uremic syndrome (HUS), each with unique causes and impacts on health.
- - In TMA, inflammation leads to endothelial damage and activates platelet and coagulation processes, often linked to low ADAMTS13 enzyme levels, particularly in cancer patients undergoing chemotherapy, which raises thrombotic risk by increasing the VWF/ADAMTS13 ratio.
- - Treatment focuses on diagnosing the specific cause and may include therapies to inhibit complement activation, supportive care, and plasmapheresis
Pediatric antiphospholipid syndrome: is it the same as an adult?
J Matern Fetal Neonatal Med
December 2024
Importance: Antiphospholipid syndrome in neonates and children is a rare, but in some cases life-threatening condition with arterial and/or venous thrombosis and/or non-thrombotic neurological, skin, ophthalmological and other manifestations.
Observations: This review highlights the available information about the features of pediatric APS, including the rare catastrophic form, the differences between pediatric and adult APS, and the role of genetic thrombophilia in APS manifestation.
Conclusions And Relevance: The clinical manifestations and treatment options for APS in children may differ from those in adults, and prescribing therapy can be challenging due to the unique clinical and morphological characteristics of the pediatric patient.
Article Synopsis
- Lu-labeled small-molecule PSMA tracers show promise as therapeutic agents for advanced prostate cancer, with potential improvements through optimized molecular design.* -
- Six novel DCL urea-based PSMA ligands were synthesized, achieving satisfactory yields and over 95% radiochemical labeling efficiency for preclinical evaluation.* -
- The study found that molecular modifications, like substituents on the aromatic fragment, significantly affect binding affinity and biodistribution, with certain variants showing improved accumulation in target tissues, although some had unfavorable pharmacokinetics.*
Article Synopsis
- Developing protein therapeutics requires optimizing their pharmacokinetic and pharmacodynamic properties, particularly to prolong their half-lives in the body.
- A study compared various half-life extension technologies (PAS polypeptides, XTEN polypeptides, and an albumin binding domain) using an HER2 affibody-drug conjugate, revealing that while these extensions lowered HER2 affinity slightly, they maintained cytotoxic effectiveness.
- The results indicated that the ABD-enhanced construct had the highest tumor uptake and the best overall performance, despite not having the longest half-life compared to others tested.
HER2 status determination is a necessary step for the proper choice of therapy and selection of patients for the targeted treatment of cancer. Targeted radiotracers such as radiolabeled DARPins provide a noninvasive and effective way for the molecular imaging of HER2 expression. This study aimed to evaluate tumor-targeting properties of three Tc-labeled DARPin G3 variants containing Gly-Gly-Gly-Cys (GC), (Gly-Gly-Gly-Ser)-Cys ((GS)C), or Glu-Glu-Glu-Cys (EC) amino acid linkers at the C-terminus and conjugated to the HYNIC chelating agent, as well as to compare them with the clinically evaluated DARPin G3 labeled with Tc(CO) using the (HE)-tag at the N-terminus.
View Article and Find Full Text PDF